Discover Great Companies Discover Great Clients
Popularity  2401   |   Feedback  1 Claim this company
No.220 Huishan District Popularity Ranking Wuxi Jiangsu No.16 Biotechnology Pharmaceuticals No.16 Innovative Drugs No.17 Sheng Ming Ke Xue Yan Jiu No.20 Sheng Ming Ke Xue No.25 Yao Products R&D No.31 Pharmaceutical Technology No.34 Biopharmaceuticals No.50 Pharmaceutical No.65 Lin Chuang Yi Xue No.99 Healthcare Technology No.99 Pharmaceutical Industrial Hua Gong / Chemistry 科技型中小企业 市级创新型中小企业 省科技型中小企业
More

Company Overview

  • Nature: Joint Venture Size: 50-99 employees Founded: 8年
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: Wuxi Huatai Innovative Drug Technology Research Institute Co., Ltd.。

Development Stage

  • Honors: 科技型中小企业 市级创新型中小企业 According to algorithm

About the Company

About Huatai Innovative Drug Research Institute. Jointly established by the academicians of the United States, Canada and the United Kingdom, the world-renowned immunologist Professor Tak Wah Mak, and the team of Professor Shi Yufang, one of the first batch of "Thousand Talents Plan" selectees of the Central Organization Department, together with the Wuxi Municipal Government, Huishan District Government and Huishan Economic Development Zone. Relying on the strong basic research strength and scientific and technological innovation capabilities of Professor Tak Wah Mak's team and Professor Shi Yufang's team, the Institute builds a research and development platform for anti-tumor small-molecule targeted drugs and monoclonal antibody drugs, a research and development center for clinical application of stem cells, and an international talent and academic exchange and international cooperation center, forming a multi-platform, multi-directional and multi-functional biomedical professional platform integrating industry, academia and research. In the next five years, Huatai Innovative Drug Research Institute will be built into an international biomedical industry research and development and transformation base for scientific and technological achievements, a public technology service platform, a high-end talent gathering center and a window for external exchanges. About Professor Tak Wah Mak. Bachelor of Science, Master of Science (University of Wisconsin, USA), PhD (University of Alberta, Canada), Doctor of Natural Science, Fellow of the Royal Society of Chemistry, Order of Canada, Fellow of the Royal Society, Foreign Associate of the National Academy of Sciences of the United States, Founding Member of the Hong Kong Academy of Sciences. Professor Mak is a world leader in immunology genes and cancer genes. His team discovered the human T-cell receptor in 1984. His published results on T-cell antigen receptor gene replication have been cited more than 1,200 times. Since this landmark discovery, Dr. Mak has focused on explaining the mechanisms of immune responses and tumorigenesis. He pioneered the use of genetically engineered mouse strains to identify genetic susceptibility genes associated with various immune diseases or different types of cancer. In particular, his research team discovered that CTLA4 is an inhibitory regulator of T-cell activation (cited more than 2,000 times), paving the way for the development of anti-CTLA4 agents for autoimmune diseases currently used in clinical practice. Professor Mak's laboratory has also made significant contributions to determining the function of PTEN (cited more than 2,000 times) and the relationship between the breast cancer susceptibility genes BRCA1 and BRCA2 and DNA repair defects. Recently, Professor Mak's research on various gene products of normal cells and cancer cells has also yielded important knowledge about their biology, which is crucial for identifying new drug targets and developing more effective cancer therapies. About Professor Shi Yufang. One of the first batch of selectees of the "Thousand Talents Plan" of the Central Organization Department, National Distinguished Expert, member of the overall group of the National 973 Scientific Research Program, chief scientist of the Major Scientific Research Program of the Ministry of Science and Technology, and convener of the National Major Research Program on Reproduction and Development. From 1988 to 1992, he obtained a PhD in Immunology from the University of Alberta, Canada; from 1992 to 1995, he conducted postdoctoral research in the Department of Immunology of the University of Toronto, Canada; from 1995 to 2001, he conducted research at the Holland Medical and Biological Research Institute of the American Red Cross and George Washington University in the United States, and was appointed as a tenured associate professor; from 2001 to 2008, he conducted research at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey in the United States, and was appointed as a tenured professor. He is currently the Director of the Institute of Health Sciences of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences / Shanghai Jiao Tong University School of Medicine, and the head of the Immunology and Adult Stem Cell Research Group. Since 1997, he has served as deputy editor and editor-in-chief of Cell Research; from 1999 to 2002, he served as deputy editor of the Journal of Immunology and has reviewed for more than 30 professional journals; in 2008, he was invited to serve as a member of the editorial board of the Journal of Biological Chemistry and chief reviewer for the stem cell section; he is a member of the Texas Stem Cell Research and Application Committee and a member of the editorial board of Oncogene. Professor Shi Yufang is a well-known immunologist and the earliest Chinese scientist to study apoptosis. Professor Shi pioneered important theories of apoptosis, established the concept of activation-induced lymphocyte apoptosis, and discovered the regulatory role of c-myc in AICD; at present, AICD has become a hot topic at the forefront of immunology research, laying an important foundation for related tumor immune regulation therapy and drug development. His early research results proving that Rapamycin promotes apoptosis of cancer cells induced by chemotherapy drugs have now become a new direction in the field of cancer treatment. He first confirmed that Fas-mediated lymphocyte apoptosis is related to stress responses or the resulting immunosuppression, which is a major discovery in the field of neuroimmune regulation; he proved the decisive role of CD4+ T cells in asthma, proposing a new direction for the treatment of allergic asthma; in the study of granzyme-dominated AICD in Th2 cells, he was the first to prove that different T cell subsets have different apoptotic pathways. Recently, he discovered the immunomodulatory properties of adult stem cells, providing an important scientific basis for the application of stem cells in the treatment of autoimmune diseases and in organ transplantation. To date, Professor Shi has published more than 100 SCI-indexed research papers, including in internationally renowned academic journals such as Nature, and his research results are of great significance for exploring stem cell regulation, cancer, infectious diseases, allergies and the pathological mechanisms of autoimmune diseases.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Huatai Innovative Drug Technology Research Institute honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 2,000万(元)
Legal Representative: 时玉舫
Date Established:
Credit Code: 91320206MA1WU42F84
Registered Address: 无锡惠山经济开发区惠山大道1699号六号楼二层

People who follow Huatai Innovative Drug Technology Research Institute also follow

Huatai Innovative Drug Technology Research Institute Competitors (Similar Companies)

“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
知识产权代理 律师事务所/法律服务 商标申请 商标事务所
新材料 聚乙烯/PE 化工/化学 塑料合金
精密机械零部件 机械零部件 生产 机械五金加工
服装/服饰 纺织 丝绸 化纤面料
工程设计 建筑幕墙 机电设备安装 门窗
环保/节能 品牌策划 环保科技/技术 艺术涂料
离心泵 多级离心泵 自动化 生产
安全设备 呼吸防护设备 生产 安全防护
开关电源 变电站 直流/DC电源 电力
造纸/造纸厂/纸业 打印纸 文化用纸 双面胶
模具 模具设计 模具开发 硅胶
塑胶零件 塑胶零配件 眼镜 配件
电机/电动机 压缩机 制冷 制冷设备
跨境服务 金融 移动支付 电子商务

Discover Great Companies, Discover Great Clients

无锡公司名录 无锡“Huishan District”公司名录 无锡“医药”公司名录 无锡“生命科学”公司名录 无锡“生命科学研究”公司名录 无锡“生物医药”公司名录 无锡“临床医学”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates